. 2018 Apr 9;4(2):00060-2017. doi: 10.1183/23120541.00060-2017

TABLE 5.

Post-immunisation immunity to influenza virus strains in pregnant study subjects

Observation time-point	Group I Agrippal S1^#			Group II Grippol Plus^¶
Observation time-point	A(H1N1, California 7, 2009)	A(H3N2, Victoria)	B(Brisbane)	A(H1N1, California 7, 2009)	A(H3N2, Victoria)	B(Brisbane)
Seroprotection level⁺ %
Baseline (gestation weeks 13–30)	16.2*	18.9	48.7**	9.5	19.0	23.8
1 month post immunisation	75.6	64.8*	94.5	72.5	87.5	90.0
3 months post immunisation	70.2	62.1*	94.5	75.6	86.4	89.1
5–6 months post immunisation (day 2 or 3 post partum)	67.5	62.1*	91.9*	64.8	78.3	75.6
8–9 months post immunisation (3rd month post partum)	62.1	51.3*	72.9	54.2	71.4	74.2
Antibody geometric mean titre ±sd
Baseline (gestation weeks 13–30)	7.9±0.2	8.7±0.3	22.9±0.2*	8.9±0.2	8.5±0.2	14.8±0.3
1 month post immunisation	57.9±0.4	41.1±0.4*	143.2±0.2*	50.4±0.3	78.2±0.3	115.8±0.31
3 months post immunisation	51.6±0.4	30.3±0.4*	108.5±0.2*	49.2±0.3	56.6±0.3	81.8±0.3
5–6 months post immunisation (day 2 or 3 post partum)	42.4±0.4	34.8±0.7*	85.7±0.3*	38.2±0.2	45.9±0.2	54.0±0.3
8–9 months post immunisation (3rd month post partum)	27.3±0.4^ƒ	23.8±0.6^ƒ	47.6±0.4^ƒƒ	30.3±0.3	30.3±0.2	44.9±0.2
Seroconversion level^§ %
1 month post immunisation	62.1	51.3*	64.8	57.1	71.4	64.2
Seroconversion factor^##
1 month post immunisation	7.2	4.7*	6.2	5.7	9.2	7.8

^#: n=37; ^¶: n=42; ⁺: proportion of immunised patients with antibody titres ≥1:40 must be ≥70%; ^§: must be ≥40%; ^##: must be ≥2.5. *: p<0.05 for differences between the compared groups; **: p<0.01 for differences between the compared groups; ^ƒ: p<0.05 for differences between 1 month post immunisation and 8–9 months post immunisation inside the reference group; ^ƒƒ: p<0.01 for differences between 1 month post immunisation and 8–9 months post immunisation inside the reference group.